Promising
Orforglipron (Foundayo)
The prediction game
Call it: rising or fading?
Where does Orforglipron (Foundayo) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: B (good evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.8/10
Orforglipron sits at the bottom of the worth-trying tier because it pairs genuinely strong, deep evidence and unmatched oral convenience with an effect size that loses to the injectables. For the indicated population, adults with obesity or weight-related metabolic disease, it is a legitimately good option: an effective, once-daily, needle-free GLP-1 with the largest launch evidence base in the class and a price below the shots. The honest caveats are that it is less powerful than injectable semaglutide or tirzepatide, that a dedicated cardiovascular outcomes trial is still years out, and that weight returns after stopping. Judge it as ongoing therapy, not a quick course. ✅ Best for: Adults with obesity, or overweight plus a metabolic condition, who want effective GLP-1 treatment without injections. People who cannot tolerate the strict fasting of oral semaglutide and want a pill they can take with food. Those who value access, cost, and adherence over squeezing out the last few percent of weight loss. Patients transitioning off an injectable GLP-1 who want an oral maintenance option, supported by the maintenance data in ATTAIN-MAINTAIN (2026). Anyone who will pair the drug with resistance training and adequate protein to protect lean mass. ❌ Avoid if: You have a personal or family history of medullary thyroid cancer or the MEN2 syndrome, an absolute contraindication for the GLP-1 class. You have had pancreatitis. You are pregnant or trying to conceive, since safety is not established. You are chasing maximum weight loss and will accept injections, where tirzepatide and injectable semaglutide do more. You take insulin or a sulfonylurea without medical supervision, given the added risk of low blood sugar shown in the diabetes trials, per Rosenstock 2025.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Promising
- Trend
- Begins with Edition 2
- Momentum
- 18.5%
- BioHarmony Score
- 5.8/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.